23andMe Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Value Chain Analysis for Deeper Insight
This 23andMe Value Chain Analysis helps you quickly understand how the company creates value across its support and primary activities. This page already shows a real preview of the analysis, so you can review the actual content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
23andMe's firm infrastructure has to coordinate privacy, lab quality, legal compliance, and finance, because trust drives both kit sales and consented research revenue. In FY2025, that pressure intensified as 23andMe filed Chapter 11 on March 23, 2025, after a major data-breach shock and weak liquidity. With more than 15 million genotyped customers, governance is a core asset, not back-office overhead.
Human Resource Management
23andMe depends on specialized talent: bioinformaticians, software engineers, lab staff, privacy and compliance experts, and customer support teams. In fiscal 2025, 23andMe reported about 600 employees, so keeping this mix matters for report accuracy, product updates, and regulated lab workflows. Hiring and retention also protect service quality when genetic data, consent rules, and customer questions all need tight handling. That talent base is a key support activity in the value chain.
Technology Development
By 2025, 23andMe had tested over 15 million customers, giving its technology layer a very large consented genetic dataset to work with. Its value creation comes from SNP genotyping, analytics software, and interpretation algorithms that turn saliva data into ancestry, health risk, and trait reports.
This same stack supports drug-discovery research by improving data curation, cohort analysis, and secure matching of genotypes with phenotype data. That matters because larger, cleaner datasets make target finding and patient stratification faster and more precise.
Procurement
In FY2025, 23andMe's procurement had to secure saliva kits, lab reagents, genotyping consumables, packaging, shipping, and cloud storage, so supplier terms directly affected kit-to-report cost. With over 15 million genotyped customers, even small savings on each kit and test batch can protect turnaround time and quality. Tight buying and vendor control also helps 23andMe avoid reagent shortages and keep data handling scalable.
23andMe's Lean FY2025 Support Kept Trust and Data Control Intact
23andMe's support activities in FY2025 were built around trust, data control, and low-cost operations: firm infrastructure absorbed Chapter 11 stress on March 23, 2025, while privacy and lab compliance protected a base of more than 15 million genotyped customers. Talent stayed lean at about 600 employees, so systems, legal, and support functions had to do more work with less.
| Support area | FY2025 data |
|---|---|
| Customers | 15M+ |
| Employees | ~600 |
| Bankruptcy filing | Mar. 23, 2025 |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
23andMe inbound logistics starts with kit parts moving through the fulfillment network and saliva samples returning from customers. In 2025, 23andMe said it had served about 15 million customers, so accessioning and chain-of-custody control matter at scale. Failed samples slow report delivery and add reprocessing cost, so quality checks protect turnaround time and margin.
Operations
23andMe's operations turn saliva into genotypic data and consumer reports, linking lab work with software that delivers ancestry, health, and trait outputs. In fiscal 2025, 23andMe reported $219.4 million of revenue, and its scale rests on more than 15 million genotyped customers, which also helps build consented research datasets for drug discovery. Accurate, fast report delivery matters because it supports repeat purchases and referrals.
Outbound Logistics
23andMe delivers results digitally in each customer account, so there is no physical shipment, last-mile handling, or warehouse cost. That lowers outbound logistics spend and lets 23andMe update reports fast, which mattered in FY2025 as the company served more than 15 million customers. Digital delivery also makes it easier to push new reports and alert users when interpretation changes.
Marketing and Sales
23andMe's Marketing and Sales is driven by direct-to-consumer e-commerce, seasonal promos, and online brand ads. In fiscal 2025, revenue was about $193 million, so demand creation matters because ancestry and health reports are discretionary buys. Clear privacy messaging also supports conversion, since trust is a core part of the purchase decision.
Service
23andMe's Service step covers account help, report interpretation, refunds or reprocessing for failed samples, and privacy requests. In FY2025, this post-sale work mattered even more as 23andMe entered Chapter 11 in March 2025, since clear support can protect trust, referrals, and research consent renewals.
For a direct-to-consumer genetics brand, good service turns a one-time kit sale into repeat engagement.
23andMe FY2025: 15M+ Customers, $193M Revenue, Chapter 11 Pressure
23andMe's primary activities in FY2025 centered on lab processing, digital report delivery, and direct online sales. It served more than 15 million customers and generated $193 million of revenue, so speed, sample quality, and trust were key. Chapter 11 in March 2025 made service and privacy handling even more important.
| FY2025 metric | Value |
|---|---|
| Customers served | 15M+ |
| Revenue | $193M |
| Chapter 11 | March 2025 |
Get Your Copy
23andMe Reference Sources
This is the actual 23andMe Value Chain Analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is taken directly from the full report, so what you see here is the same content included in your download after checkout.
Frequently Asked Questions
The core driver is the conversion of 1 saliva sample into 3 consumer outputs: ancestry, health predispositions, and trait reports. That workflow also creates a second asset, consented genetic data, which can support research collaborations and drug discovery. Value depends on accurate genotyping, strong privacy controls, and fast digital delivery rather than physical distribution.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.